[ad_1]
Zydus Lifesciences Ltd on Friday mentioned it has obtained last approval from the US well being regulator to market its generic model of Triazolam tablets used on a short-term foundation to deal with insomnia. The approval granted by the US Meals and Drug Administration (USFDA) is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the corporate mentioned in a regulatory submitting.
The medication is used on a short-term foundation to deal with insomnia — problem falling asleep or staying asleep. It really works by slowing exercise within the mind to permit sleep.
It will likely be manufactured on the group’s formulation manufacturing facility at Moraiya, Ahmedabad, the corporate mentioned.
Triazolam tablets had annual gross sales of USD 11.7 million within the US, the corporate mentioned, citing IQVIA MAT September 2022 knowledge.
[ad_2]
Source link
